The MyCheckpoint trial (NCT04150965) demonstrated that blockage of TIGIT and LAG-3 in heavily pretreated MM patients reshape the immune microenvironment and led to durable responses [32], while another trial (NCT04354246) is still ongoing. The gene discussed is LAG3; the disease is Miyoshi myopathy.